Cargando…

Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer

Somatic alterations in the epidermal growth factor receptor gene (EGFR) result in aberrant activation of kinase signaling and occur in ∼15% of non-small cell lung cancers (NSCLC). Patients diagnosed with EGFR-mutant NSCLC have good initial clinical response to EGFR tyrosine kinase inhibitors (EGFR T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shaurova, Tatiana, Zhang, Letian, Goodrich, David W., Hershberger, Pamela A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121227/ https://www.ncbi.nlm.nih.gov/pubmed/32292420 http://dx.doi.org/10.3389/fgene.2020.00281

Ejemplares similares

Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance
por: Shaurova, Tatiana, et al.
Publicado: (2020)

A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer
por: Shaurova, Tatiana, et al.
Publicado: (2023)

Identification of Six Prognostic Genes in EGFR–Mutant Lung Adenocarcinoma Using Structure Network Algorithms
por: Zhang, Haomin, et al.
Publicado: (2021)

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review
por: Guo, Yijia, et al.
Publicado: (2020)

Long non-coding RNAs in non-small cell lung cancer: implications for EGFR-TKI resistance
por: Liu, Detian, et al.
Publicado: (2023)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo
por: Verone-Boyle, Alissa R., et al.
Publicado: (2015)

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors
por: Heppner, David, et al.
Publicado: (2023)

KRAS G12C-Mutant Non-Small-Cell Lung Adenocarcinoma: First Documented Report in the Arabian Gulf
por: Alsulaiman, Abdullah S, et al.
Publicado: (2022)

Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer
por: Gao, Liyuan, et al.
Publicado: (2022)

Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Associations of mRNA:microRNA for the Shared Downstream Molecules of EGFR and Alternative Tyrosine Kinase Receptors in Non-small Cell Lung Cancer
por: Wang, Fengfeng, et al.
Publicado: (2016)

Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis
por: Kuan, Feng-Che, et al.
Publicado: (2015)

Relationship between the image characteristics of artificial intelligence and EGFR gene mutation in lung adenocarcinoma
por: Zhou, Guoping, et al.
Publicado: (2023)

BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
por: Fan, Fushun, et al.
Publicado: (2020)

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
por: Yan, Dan, et al.
Publicado: (2021)

Minimal residual disease in EGFR-mutant non-small-cell lung cancer
por: Bain, Nathan T., et al.
Publicado: (2022)

Wnt1 Lineage Specific Deletion of Gpr161 Results in Embryonic Midbrain Malformation and Failure of Craniofacial Skeletal Development
por: Kim, Sung-Eun, et al.
Publicado: (2021)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Kwon, Byoung Soo, et al.
Publicado: (2017)

Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
por: Tone, Mari, et al.
Publicado: (2023)

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
por: Niederst, Matthew J., et al.
Publicado: (2015)

Utilizing Publicly Available Cancer Clinicogenomic Data on CBioPortal to Compare Epidermal Growth Factor Receptor Mutant and Wildtype Non-Small Cell Lung Cancer
por: Dhar, Chirag
Publicado: (2021)

RAD sequencing resolves fine-scale population structure in a benthic invertebrate: implications for understanding phenotypic plasticity
por: Vendrami, David L. J., et al.
Publicado: (2017)

Path-ATT-CNN: A Novel Deep Neural Network Method for Key Pathway Identification of Lung Cancer
por: Yuan, Lin, et al.
Publicado: (2022)

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer
por: Saifon, Woraseth, et al.
Publicado: (2022)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR ‐mutant non‐small cell lung cancer
por: Lei, Si‐Yu, et al.
Publicado: (2023)

Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer
por: Farnsworth, Dylan A., et al.
Publicado: (2021)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2014)

Clinicopathological features of patients with transformation from EGFR mutant lung adenocarcinoma to small cell lung cancer
por: Bai, Wenwen, et al.
Publicado: (2021)

Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment
por: Deng, Shanshan, et al.
Publicado: (2020)

Unlocking phenotypic plasticity provides novel insights for immunity and personalized therapy in lung adenocarcinoma
por: Wang, Feng, et al.
Publicado: (2022)

The Path to microRNA Therapeutics in Psychiatric and Neurodegenerative Disorders
por: Chan, Anthony W. S., et al.
Publicado: (2012)

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
por: Eggermont, Carolien, et al.
Publicado: (2022)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

miRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance
por: Ricciuti, Biagio, et al.
Publicado: (2015)

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
por: Vaclova, Tereza, et al.
Publicado: (2021)

Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report
por: Jiang, Yiqian, et al.
Publicado: (2021)

Epithelial-mesenchymal transition is associated with osteopontin-induced EGFR‑TKI resistance in EGFR mutant non-small cell lung cancer
por: Chen, Junjie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aglme3b6okej2mgtlmtp242f3g